Report Summary 1. Report Industry Investment Rating There is no information provided regarding the industry investment rating in the given content. 2. Report's Core View - The report focuses on the in - depth research of Anxu Bio, a biotech company in the medical device industry. It highlights the company's comprehensive strength, including its strong R & D capabilities, diverse product lines, and strategic layout for future development. Anxu Bio aims to become a leading enterprise in the international in - vitro diagnostic industry through continuous innovation and market expansion [23][24]. 3. Summary by Related Catalogs 3.1. Research Basic Situation - The research object is Anxu Bio, belonging to the medical device industry. The reception time was on May 20, 2025. The listed company's reception staff included the company's chairman and general manager Ling Shisheng, board secretary Han Jun, financial controller Kang Min, and independent director Zhang Guobiao [16]. 3.2. Detailed Research Institutions - The relevant personnel participated in the "2024 Annual Report and 2025 First - Quarter Performance Briefing" [19]. 3.3. Research Institution Proportion There is no specific information provided about the research institution proportion in the given text. 3.4. Main Content Data 3.4.1. Company Basic Situation Introduction - Anxu Bio was founded in 2008 and went public on the Science and Technology Innovation Board in November 2021. It is a high - tech biotech enterprise integrating R & D, production, and sales of in - vitro diagnostic reagents, POCT instruments, and biological raw materials. It has achieved an integrated industrial chain layout from upstream core biological raw materials to diagnostic reagents and instruments [23]. - The company has eight major fields of POCT reagents and related supporting instruments, covering drug testing, infectious disease testing, etc., and its products are sold in more than 150 countries and regions. It also actively strategically layouts in the pharmaceutical field, such as third - party medical testing laboratories, pet health management, and family health management [23][24]. - In the future, the company will continue to increase investment in R & D and production of biological raw materials, improve the performance of POCT reagents and instruments, and focus on both international and domestic markets to become a leading enterprise in the international in - vitro diagnostic industry [24]. 3.4.2. Q&A Session Main Content - **Financial Performance**: In 2024, the company's operating income was 540.6985 million yuan, net profit attributable to the parent company was 192.2953 million yuan, and net profit attributable to the parent company after deducting non - recurring gains and losses was 37.8979 million yuan. In the first quarter of 2025, the operating income was 115.2965 million yuan, net profit attributable to the parent company was 34.0296 million yuan, and net profit attributable to the parent company after deducting non - recurring gains and losses was 22.7603 million yuan [25]. - **R & D Breakthroughs and Advantages**: The company has built nine technology platforms, forming a trinity industrial chain layout of raw materials, reagents, and instruments. In 2024, it added 44 authorized patents (including 13 invention patents), with a total of 305 authorized patents, and added 606 international and domestic certifications, with a total of 1580 certifications, including EU CE and US FDA [25]. - **Business Expansion**: The company promotes the iteration of core products, builds a diversified product matrix, and explores performance growth potential in fields such as pet health management, family health management, and medical testing laboratories, advancing the Anxu Bio medical and health ecosystem strategy [26]. - **Future Profit Growth Drivers**: The company will focus on technological innovation, increase R & D investment, explore frontier technology fields, continue to expand overseas markets while increasing efforts in the domestic market, and consider expanding medical and health - related business through cooperation, investment, or mergers and acquisitions [26]. - **GluMate App**: With the rising global prevalence of chronic diseases, GluMate is launched to improve the health management of chronic disease patients. It aims to transform from single - detection to full - cycle service and build a chronic disease monitoring product system centered on GluMate, providing intelligent and personalized chronic disease management solutions [27]. - **2024 Dividend Policy**: In 2024, the company plans to distribute a cash dividend of 8 yuan per 10 shares (tax - included) to all shareholders, with a total cash dividend of 152.499366 million yuan (including the interim dividend), accounting for 79.30% of the net profit attributable to listed company shareholders in the 2024 consolidated statements [28]. - **Market Expansion Measures and Achievements**: The company adheres to the "international + domestic" dual - wheel drive strategy. Overseas, its products are sold in more than 150 countries and regions, and it participates in well - known exhibitions to enhance brand influence. Domestically, it has obtained new product registration certificates and promoted brand sales through online and offline channels. It has also established subsidiaries in Singapore, the United States, and Europe to optimize the global marketing network [28][29].

Core Viewpoint - The 2024 Annual General Meeting of Hangzhou Anxu Biotechnology Co., Ltd. will address various proposals including the work reports of the Board of Directors and Supervisors, the annual financial report, and profit distribution plans, reflecting the company's operational performance and governance structure [1][6][22]. Group 1: Meeting Procedures and Regulations - Shareholders must provide identification and authorization documents to attend the meeting, ensuring orderly conduct and protection of shareholder rights [2][4]. - The meeting will combine on-site and online voting, with specific time slots for each voting method [4][5]. - The agenda includes sign-in, introduction of attendees, reading of meeting rules, and sequential voting on proposals [5][6]. Group 2: Financial Performance - The company reported a net profit attributable to shareholders of 192.30 million yuan, a 35.85% increase year-on-year, while the net profit after deducting non-recurring items decreased by 27.6% to 37.90 million yuan [8][23]. - Total assets as of the end of 2024 were 5.77 billion yuan, a slight decrease of 0.35% compared to the previous year [23][24]. - The company achieved a revenue of approximately 540.70 million yuan, reflecting a growth of 7.42% from the previous year [24]. Group 3: Governance and Oversight - The Board of Directors and Supervisors have conducted their duties in accordance with relevant laws and regulations, ensuring compliance and protecting shareholder interests [17][22]. - The independent directors provided reports summarizing their activities and recommendations for the upcoming year, emphasizing their role in corporate governance [6][13]. - The Supervisory Board confirmed that the company operated within legal frameworks and that there were no violations or irregularities in financial reporting [20][22]. Group 4: Future Plans - The company aims to enhance its governance structure and internal controls, focusing on sustainable development and maximizing shareholder value [14][15]. - Plans for 2025 include advancing technological innovation, expanding product lines, and improving operational efficiency to strengthen market competitiveness [14][15].

杭州安旭生物科技股份有限公司 2024 年年度股东大会会议资料 杭 州 安 旭 生 物 科 技 股 份 有 限 公 司 2024 年年度股东大会会议资料 股票简称：安旭生物 2025 年 5 月 22 日 1 股票代码：688075 杭州安旭生物科技股份有限公司 2024 年年度股东大会会议资料 目 录 | 东 2024 | | | 年 | | | 年 | | | 度 | | 股 | | | | | 大 | | 会 | | | 须 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 知……………………………………………………………………………..………3 | | | | | | | | | | | | | | | | | | | | | | | | | 东 2024 | | | 年 | | | 年 | | | 度 | | 股 | | | | | 大 | | ...

民生证券股份有限公司 关于杭州安旭生物科技股份有限公司 首次公开发行股票并在科创板上市之保荐总结报告书 根据《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股票 上市规则》、《上海证券交易所科创板上市公司自律监管指引第1号——规范 运作》等有关法律、法规的规定，民生证券股份有限公司（以下简称"民生证 券"或"保荐机构"）作为杭州安旭生物科技股份有限公司（以下简称"安 旭生物"或"公司"）首次公开发行股票并在科创板上市的保荐机构，负责安 旭生物上市后的持续督导工作，持续督导期间为2021年11月18日至2024年12 月31日。2024年12月31日，持续督导期已届满，民生证券根据《证券发行上 市保荐业务管理办法》《上海证券交易所科创板股票上市规则》等有关规定， 出具本保荐总结报告书。 一、 保荐机构及保荐代表人承诺 保荐总结报告书及其相关资料的内容不存在虚假记载、误导性陈述或重大 遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法律责任。 保荐机构及保荐代表人自愿接受中国证监会对保荐总结报告书相关事项进 行的任何质询与调查。 保荐机构及保荐代表人自愿接受中国证监会按照《证券发行上市保荐业务 管 ...

本次投资者说明会以网络互动形式召开，公司将针对 2024 年度及 2025 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 证券代码：688075 证券简称：安旭生物 公告编号：2025-012 杭州安旭生物科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ?会议召开时间：2025 年 05 月 20 日 （星期二） 14:00-15:00 ? 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） ?会议召开方式：上证路演中心网络互动 ?投资者可于 2025 年 05 月 13 日 （星期二） 至 05 月 19 日 （星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jun.yu@d ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-012 杭州安旭生物科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 05 月 20 日 （星期二） 14:00-15:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 05 月 13 日 （星期二） 至 05 月 19 日 （星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jun.yu@diareagent.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 杭州安旭生物科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 30 日 发布公司 2024 年年度报告及 2025 年第一季度报告，为便于广 ...

Company Overview - Anxu Bio focuses on the research, production, and sales of POCT (Point-of-Care Testing) reagents and instruments, with a product range covering eight major areas including drug detection, infectious disease detection, chronic disease detection, pregnancy detection, tumor detection, myocardial detection, biochemical detection, and allergen detection [1] - The company has developed a proprietary technology platform for antigen-antibody production and has established mature immunochromatography and dry biochemical diagnostic technology platforms [1] - Anxu Bio's products are exported to over 150 countries, including the USA, Germany, the UK, Canada, Russia, Mexico, Thailand, Indonesia, and Poland, positioning it as one of the few Chinese suppliers capable of competing with multinational in vitro diagnostic giants in the international POCT market [1] Financial Performance - For Q1 2025, Anxu Bio reported a revenue of 115 million yuan, representing a year-on-year decrease of 10.90%, and a net profit of 34.03 million yuan, down 51.52% year-on-year [2] - The company's gross profit margin stands at 42.32% [2] Market Position - As of May 9, Anxu Bio's stock closed at 36.34 yuan, with a rolling price-to-earnings (PE) ratio of 29.58 times, and a total market capitalization of 4.618 billion yuan [1] - The average PE ratio for the medical device industry is 48.98 times, with a median of 36.16 times, placing Anxu Bio at the 67th position in the industry ranking [1][2] - As of Q1 2025, six institutions hold shares in Anxu Bio, including four funds, with a total holding of 50.38 million shares valued at 1.998 billion yuan [1]

Core Insights - Anxu Bio is a technology-driven POCT (point-of-care testing) company with nine technology platforms covering various testing fields, forming a comprehensive industry chain of raw materials, reagents, and instruments [1] - In 2024, the company invested 101 million yuan in R&D, accounting for 18.67% of its revenue, and achieved significant advancements in product certifications and patents [1][2] - The company reported a revenue of 541 million yuan in 2024, a year-on-year increase of 7.42%, and a net profit of 192 million yuan, reflecting a substantial growth of 35.85% [4] R&D and Product Development - Anxu Bio's R&D efforts led to the acquisition of 44 new patents and 592 international certifications, enhancing its product matrix and technological capabilities [1] - The company has recently received domestic medical device registration for several products, indicating progress in expanding its domestic market [1] Financial Performance and Shareholder Returns - Since its listing in 2021, Anxu Bio has distributed a total of 794 million yuan in dividends, with a planned cash dividend of 8 yuan per 10 shares for 2024, amounting to 15.25 million yuan, which represents 79.30% of the net profit [2] Market Expansion and Strategic Initiatives - Anxu Bio is extending its business into the pet medical market through its subsidiary, aiming to leverage its experience in pet testing products [2] - The company has launched a chronic disease management app, enhancing its product offerings in home health management and facilitating seamless health data utilization [2]

杭州安旭生物科技股份有限公司 舆情管理制度 第一章 总则 第一条 为提高杭州安旭生物科技股份有限公司（以下简称"公司 "）应 对各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情 对公司股价、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者合 法权益，根据《上海证券交易所股票上市规则》等相关法律法规规定及《杭州 安旭生物科技股份有限公司章程》（以下简称"公司章程 "），结合公司实 际情况制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第二章 舆情管理的组织体系及工作职责 （三）协调和组织各类舆情处理过程中对外宣传报道工作； （四）负责做好向地方监管局的信息上报工作及上海证券交易所的信息沟 通工作； （五）各类舆情处理过程中的其他事项。 1 第六条 公司董事会办公室负责对媒体信息的日常管理，及时收集、分析、核 实对公司有重 ...

杭州安旭生物科技股份有限公司 市值管理制度 第一章 总则 第一条为加强杭州安旭生物科技股份有限公司（以下简称"公司"）市值管理， 切实推动公司投资价值提升，增强投资者回报，维护投资者利益，根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司信息披露管理办法》 《上市公司监管指引第10 号——市值管理》等法律法规、规范性文件和《公司 章程》等规定，结合公司实际情况，制定本制度。 第二条本制度所称市值管理，是指公司以提高公司质量为基础，为提升 公 司投资价值和股东回报能力而实施的战略管理行为。 第三条市值管理的基本原则包括： （一）合规性原则：公司应当在严格遵守相关法律法规、规范性文件、 自 律监管规则以及《公司章程》等内部规章制度的前提下开展市值管理工作。 第二章 市值管理机构与人员 第四条公司董事会是市值管理工作的领导机构，具体负责以下工作： （一）制定公司市值管理总体规划。董事会战略委员会应当重视公司质量 的提升， 根据当前业绩和未来战略规划就公司投资价值制定长期目标，在公司 1 治理、日常经营、并购重组及融资等重大事项决策中充分考虑投资者利益和回 报，坚持稳健经营，避免盲目扩张，不断提升公司投 ...